Memorial Sloan Kettering Cancer Center, alongside Genentech and BioNTech, are undertaking a clinical trial for a customized mRNA vaccine for pancreatic cancer. This vaccine, currently in phase 2, targets neoantigens found in tumor cells, potentially providing long-term protection against cancer recurrence. This personalized vaccine, whose genetic sequencing is managed by BioNTech in Germany, revealed promising results in its phase 1 trial. The ongoing phase 2 trial aims to establish the vaccine's safety and efficacy, potentially revolutionizing treatment for pancreatic cancer and other types.
Full article here: https://medium.com/@lawsuithelpdesk/revolutionizing-pancreatic-cancer-treatment-the-game-changer-mrna-vaccine-trial-at-memorial-sloan-544af5568199